Compare TLIH & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TLIH | ERNA |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.0M |
| IPO Year | 2025 | N/A |
| Metric | TLIH | ERNA |
|---|---|---|
| Price | $0.49 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.2K | ★ 187.4K |
| Earning Date | 09-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $51,204,304.00 | $1,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $1.08 |
| 52 Week High | $7.00 | $11.07 |
| Indicator | TLIH | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.72 |
| Support Level | N/A | $1.15 |
| Resistance Level | N/A | $1.29 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 40.63 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental and provision of engineering consultancy services to port, construction, civil engineering and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment and port machinery. The company operates in Singapore and Other International Countries.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.